Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Cefovecin

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Powder Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:46 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:46 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:46 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Cefovecin

Cefovecin

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Powder Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Cefovecin

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). Species commonly shown: Both, Dog, Cat.

Generic name
Cefovecin
Brand names
Convenia®, Cefovecin Sodium for Injection
Manufacturer
Multiple FDA sponsors
Species
Both, Dog, Cat
Dosage forms
Powder, Lyophilized powder for injection
Prescription
Prescription required
Completeness
100%
Validation
Needs review
Brand names
Convenia® Cefovecin Sodium for Injection
Dosage forms
Powder Lyophilized powder for injection

Indications / Uses

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Anorexia, Diarrhoea, Not eating.

FAQ

Both, Dog, Cat

Yes. Roxee shows this as prescription-only.

Powder, Lyophilized powder for injection

Related Medications

Bedinvetmab Same category: Pain & Arthritis Carprofen Same category: Pain & Arthritis Deracoxib Same category: Pain & Arthritis Gabapentin Same category: Pain & Arthritis Grapiprant Same category: Pain & Arthritis Meloxicam Same category: Pain & Arthritis

Related Conditions

Abscesses (cat bite abscess) Pyoderma (superficial/deep)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • For subcutaneous use in dogs and cats only
  • Maximum treatment should not exceed 2 injections
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Bilirubinuria (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Cefovecin; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-014449
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 26 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-014449
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-014449
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Bilirubinuria (1 reports), Behavioral disorder (unspecified) (1 reports), Basophilia (1 reports)

Body systems represented Signal grouping

Digestive (1), Skin & allergy (4), Neurologic (1), Behavior (2)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (26 reports), Dog (6 reports)

Breed metadata in reports Metadata only

Domestic Shorthair (3), Schnauzer - Miniature (1), Domestic Longhair (1), Ragdoll (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Cefovecin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

For subcutaneous use in dogs and cats only, Maximum treatment should not exceed 2 injections, wobbly/unsteady walking, Loss of appetite, Bilirubinuria

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Cefovecin brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2026-US-014449 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • For subcutaneous use in dogs and cats only
  • Maximum treatment should not exceed 2 injections
  • wobbly/unsteady walking
  • Loss of appetite
  • Bilirubinuria

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Bilirubinuria (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Cat, Dog
Indication / use
For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus …
Form / route / dose
Form: Lyophilized powder for injection, Powder
Route: Subcutaneous
Confirm product label and patient-specific plan.
Warnings
  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and …
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Lyophilized powder for injection, Powder
Identifiers:
ANADA: 200812 NADA: 141285 NDC Package: 17033-002-01 NDC Package: 54771-1520-1 NDC Product: 17033 NDC Product: 54771
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
66
Matching reports
5
Active filters
2
Selected filters
Reaction: Not eating Clear Body system: Neurologic Clear
Reset
Drill into common report signals
Lethargy (see also Central nervous system depression in Neurological) (16) Intentional misuse (12) Not eating (12) Behavioural disorder NOS (10) Other (62) Neurologic (27) Digestive (26) Effectiveness (12)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-014358

Received 2026-03-16 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (5.37 Kilogram)
Age
1-3 years (2 Year)
Sex
Female Neutered
Region
USA
Reactions
VomitingLethargy (see also Central nervous system depression in Neurological)High pancreatic-specific lipaseDehydrationNeutrophiliaPancreatitis NOSNot eatingLeukocytosis NOSDepressionElevated gamma-glutamyl transferase (GGT)AzotaemiaAnaemia NOSHypoalbuminaemiaAbdominal effusionHyperglycaemiaElevated symmetrical dimethylarginine (SDMA)Elevated blood urea nitrogen (BUN)Elevated creatinineHyponatremiaHypochloraemiaLow serum alkaline phosphatase (ALP)Decreased red blood cell countDecreased haemoglobinProteinuria
Body systems
DigestiveNeurologicOther
Outcomes
Recovered/Normal

USA-USFDACVM-2026-US-008052

Received 2026-02-16 · MSK · MSK

Serious
Species
Dog
Breed
['Chihuahua', 'Poodle (unspecified)']
Size / weight
Under 10 lb (3.937 Kilogram)
Age
8+ years (16 Year)
Sex
Male Neutered
Region
USA
Reactions
Renal failureDeath by euthanasiaLeukocytosis NOSElevated blood urea nitrogen (BUN)Elevated serum alkaline phosphatase (ALP)Not eatingNot drinkingConstipationLethargy (see also Central nervous system depression in Neurological)HyperglycaemiaAbnormal radiograph findingCorneal ulcerWalking slowlyNeck pain - neurologicalOral massToothache
Body systems
OtherNeurologic
Outcomes
Euthanized

USA-USFDACVM-2026-US-007418

Received 2026-02-09 · MSK · MSK

Serious
Species
Cat
Breed
Domestic Shorthair
Size / weight
10-24 lb (8.7 Kilogram)
Age
1-3 years (2.8 Year)
Sex
Male Neutered
Region
USA
Reactions
Lack of efficacy - NOSNot eatingLethargy (see also Central nervous system depression in Neurological)General pain (see other SOCs for specific pain)Facial oedemaTrigeminus paralysisOral ulcerationIntentional misuse
Body systems
EffectivenessOtherNeurologic
Outcomes
Ongoing

USA-USFDACVM-2025-US-071120

Received 2025-12-01 · MSK · MSK

Non-serious
Species
Cat
Breed
Maine Coon
Size / weight
10-24 lb (5.942 Kilogram)
Age
8+ years (8 Year)
Sex
Male Unknown
Region
USA
Reactions
Pain NOSLamenessNot eatingFeverHigh pancreatic-specific lipaseLethargy (see also Central nervous system depression in Neurological)VomitingLack of efficacy - NOS
Body systems
OtherNeurologicDigestiveEffectiveness
Outcomes
Recovered/Normal

USA-USFDACVM-2025-US-070810

Received 2025-12-01 · MSK · MSK

Serious
Species
Dog
Breed
['Shih Tzu', 'Spitz - German Pomeranian']
Size / weight
Under 10 lb (3.402 Kilogram)
Age
8+ years (8 Year)
Sex
Female Neutered
Region
USA
Reactions
Seizure NOSDeathMedication error NOSNot eatingLeucocytosis NOSPain NOSElevated lactateHyperglycaemiaAbdominal discomfortAbnormal radiograph findingNeutrophiliaMonocytosisElevated triglyceride
Body systems
NeurologicOther
Outcomes
Died

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
26
Species represented
2
Grouped by Body System
Digestive (1) · Loss of appetite Skin & allergy (4) · Hair loss at application site, Biting - pruritus, Application site hair loss Neurologic (1) · Unsteady walking (ataxia) Behavior (2) · Behavioral disorder (unspecified), Aggression Other (24) · Bloated, Bilirubinuria, Basophilia
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Digestive 1 Cat 1
Other 1 Cat 1
Behavior 1 Cat 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Cat (26) Dog (6)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Serious - 1
Digestive Cat Serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Skin & allergy Cat Serious - 1
Other Cat Non-serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Cefovecin Sodium for Injection SPL · SPL Convenia® SPL · SPL FOI Summary oA 200-812 Approved June 24, 2025.pdf FOI · FOI

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

2

FOI

2

Cefovecin Sodium for Injection

SPL · SPL

Open original
FDA Structured Product Label

Cefovecin Sodium for Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Qilu Animal Health Products Co., Ltd.
ANADA
200-812
Status
RX
Form
Lyophilized powder for injection
Route
Subcutaneous
Composition / specifications
Each mL of reconstituted lyophile contains 80 mg of cefovecin as the sodium salt

Dogs

Indication

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosage

Administer 3.6 mg/pound (lb) (8 mg/kilograms (kg)) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

Dosage

Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.

Convenia®

SPL · SPL

Open original
FDA Structured Product Label

Convenia®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-285
Status
RX
Form
Powder
Route
Subcutaneous
Species
Dog • Cat
Composition / specifications
Each milliliter of constituted solution contains 80 milligrams cefovecin as the sodium salt.

Cats

Indication
For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only.

Dogs

Indication
For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

FOI Summary oA 200-812 Approved June 24, 2025.pdf

FOI · FOI

Open original

ucm062340.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:46 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:46 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Lyophilized powder for injection, Powder • Subcutaneous
Applications: ANADA 200-812 • NADA 141-285
Documents: 2 (FOI: 2) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 82 • Cat 227 • View
Case summaries: 66 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Bilirubinuria (1) Behavioral disorder (unspecified) (1) Basophilia (1) Azotaemia (1) Autoimmune disorder NOS (1) Ascites (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200812 NADA: 141285 NDC Package: 17033-002-01 NDC Package: 54771-1520-1 NDC Product: 17033 NDC Product: 54771
Package NDC Product NDC Form / Route Status
17033-002-01 17033 -
54771-1520-1 54771 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 113 Clinical 9 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Clinical, 2026-04-11)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Anorexia, Diarrhoea, Not eating. (Clinical, 2026-04-11)
  • usage: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infectio… (Clinical, 2026-04-15)
  • usage: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infectio… (Clinical, 2026-04-15)
  • usage: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infectio… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Official, 2026-04-22)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Official, 2026-02-12)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-08-06)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-08-05)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-08-04)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-08-03)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-08-02)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-08-01)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-07-31)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-07-30)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-07-29)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-16 13:27 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 13:27 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 13:27 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 13:27 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 13:27 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 13:27 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-15 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-15 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-15 10:06 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-15 10:06 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-15 10:06 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-15 10:06 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Cefovecin Sodium for Injection
RX
Cefovecin sodium
Lyophilized powder for injection • Subcutaneous
Label highlights
Official documents
Qilu Animal Health Products Co., Ltd. ANADA 200-812 Approved Jul 1, 2025
Convenia®
RX
Cefovecin sodium
Powder • Subcutaneous
Label highlights
Official documents
Zoetis Inc. NADA 141-285 Approved Oct 2, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
Each mL of reconstituted lyophile contains 80 mg of cefovecin as the sodium salt
Dogs
Indication

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosage

Administer 3.6 mg/pound (lb) (8 mg/kilograms (kg)) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.

Limitations
Cats
Indication

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

Dosage

Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat
Composition / specifications
Each milliliter of constituted solution contains 80 milligrams cefovecin as the sodium salt.
Cats
Indication
For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only.
Dogs
Indication
For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Hair loss at application site (1) • Cat Biting - pruritus (1) • Cat Application site hair loss (1) • Cat Alopecia local (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Cat Aggression (1) • Cat

Showing top 5 for Behavior.

Other
Bloated (1) • Cat Bilirubinuria (1) • Cat Basophilia (1) • Cat Azotaemia (1) • Cat Autoimmune disorder NOS (1) • Dog
Show more (19)
Ascites (1) • Cat Arched back (1) • Dog Application site skin scaling (1) • Cat Anisocoria (1) • Cat Anaphylaxis (1) • Cat Anal sac disorder (1) • Dog Anaemia NOS (1) • Cat Agitation (1) • Cat Adipsia (1) • Cat Acting tense (1) • Cat Abscess NOS (1) • Dog Abnormal ultrasound finding (1) • Cat Abnormal radiograph finding (1) • Cat Abnormal menace reflex test (1) • Cat Abnormal histology NOS (1) • Cat Abnormal cytology (1) • Cat Abdominal effusion (1) • Cat Abdominal discomfort (1) • Dog Abdominal cavity disorder NOS (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Schnauzer - Miniature, Male, 5 year, 10.16 kilogram • Drug: MSK, Injection, Subcutaneous • Reactions: Lameness, Wobbliness, Tiredness (lethargy), Unable to walk, Weakness… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-014449
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 5.00 Year
  • Weight: 10.160 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
Reactions Reported:
Lameness Wobbliness Tiredness (lethargy) Unable to walk Weakness Fever Immune-mediated polyarthritis Gastritis Abdominal cavity disorder NOS Abnormal ultrasound finding Hyperproteinaemia Lymphopenia Eosinopenia Medication error NOS
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 10 year, 3.27 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.32 mL per animal • Reactions: Loss of appetite, Intentional misuse, Adipsia, Constipation, Tiredness (lethargy)… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-014426
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 3.270 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 0.32 mL per animal
Reactions Reported:
Loss of appetite Intentional misuse Adipsia Constipation Tiredness (lethargy) Unsteady walking (ataxia) Hiding
Outcomes: Ongoing

Cat, Domestic Longhair, Female, 18 year, 2.88 kilogram • Drug: MSK, Injection, Subcutaneous • Reactions: Intentional misuse, Unsteady walking (ataxia), Lumbar pain • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-014378
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 18.00 Year
  • Weight: 2.880 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
Reactions Reported:
Intentional misuse Unsteady walking (ataxia) Lumbar pain
Outcomes: Recovered/Normal

Cat, Ragdoll, Male, 10 year, 5.498 kilogram • Drug: MSK, Unknown • Reactions: Head tilt - neurological disorder, Unsteady walking (ataxia) • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-014107
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 5.498 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Head tilt - neurological disorder Unsteady walking (ataxia)
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Male, 11 week, 1.4 kilogram • Drug: MSK, Parenteral • Reactions: Soft stool, Bloated, Disorder of gastrointestinal flora, Vomiting, Depression… • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2026-US-014167
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 11.00 Week
  • Weight: 1.400 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Parenteral
Reactions Reported:
Soft stool Bloated Disorder of gastrointestinal flora Vomiting Depression Increased heart rate Bloody stool Bloody diarrhoea
Outcomes: Recovered/Normal

Cat, Cat (other), Unknown • Drug: MSK, Injection, Unknown • Reactions: Lack of efficacy - NOS, Medication error NOS • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-013786
  • Serious AE: No
  • Treated For AE: No
  • Sex: Unknown
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Injection
Reactions Reported:
Lack of efficacy - NOS Medication error NOS
Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 11 year, 5.9 kilogram • Drug: MSK, Injection, Subcutaneous • Reactions: Thrombocytopenia • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-012908
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 5.900 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
Reactions Reported:
Thrombocytopenia
Outcomes: Ongoing

Dog, Shepherd Dog - Australian, Female, 2 month, 3.45 kilogram • Drug: MSK, Injection, Subcutaneous, Frequency: 12 per hour • Reactions: Tiredness (lethargy), Vomiting, Loss of appetite, Tachycardia, Fever… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013736
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 2.00 Month
  • Weight: 3.450 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Frequency: 12 per hour
Reactions Reported:
Tiredness (lethargy) Vomiting Loss of appetite Tachycardia Fever Increased salivation Abnormal radiograph finding Neurological signs NOS Intentional misuse Agitation
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.